EditorialsDefining nonalcoholic fatty liver disease: Implications for epidemiologic studies☆,☆☆
References (23)
- et al.
Treatment of hepatitis C patients with normal aminotransferases levels
Clin Liver Dis
(1999) - et al.
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States
Gastroenterology
(2003) - et al.
Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients
Am J Gastroenterol
(1999) - et al.
Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology
J Hepatol
(2001) - et al.
Liver fibrosis in overweight patients
Gastroenterology
(2000) - et al.
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
Gastroenterology
(2002) - et al.
Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis?
Gastroenterology
(2002) - et al.
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity
Gastroenterology
(1999) - et al.
Non-alcoholic fatty liver: another feature of the metabolic syndrome?
Clin Nutr
(1999) Deaths and hospitalizations from chronic liver disease and cirrhosis–United States, 1980–1989
MMWR Weekly
(1993)
Liver biopsy
N Engl J Med
Cited by (165)
Impact of nonalcoholic fatty liver disease on the risk of gallbladder polyps in lean and non-obese individuals: A cohort study
2024, Hepatobiliary and Pancreatic Diseases InternationalPeripheral Artery Disease and Risk of Fibrosis Deterioration in Nonalcoholic Fatty Liver Disease: A Prospective Investigation
2020, Biomedical and Environmental SciencesPrediction of fatty liver disease using machine learning algorithms
2019, Computer Methods and Programs in BiomedicineCitation Excerpt :Additionally, a significant amount of studies described that FLD patients were asymptomatic, and pointed out specific cause of fatty liver disease. They mentioned that elevation of circulatory concentrations biomarkers such as serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT)are mainly responsible for hepatic damage [26,27]. Recently, several studies have reported classification results to correctly identify fatty liver patients and non-fatty liver patients.
Nonalcoholic fatty liver disease
2018, Practical Hepatic Pathology: A Diagnostic Approach: Second EditionVisceral and subcutaneous fat, muscle mass, and liver volume as noninvasive predictors of the progress of non-alcoholic fatty liver disease
2023, Egyptian Journal of Radiology and Nuclear MedicineNonalcoholic Fatty Liver Disease as a Risk Factor for Severe Cholangitis
2023, Israel Medical Association Journal
- ☆
Address requests for reprints to: Anna Mae Diehl, M. D., Departments of Medicine and Epidemiology, The Johns Hopkins University Schools of Medicine and Public Health Baltimore, 720 Rutland Street, 912 Ross Building, Maryland 21205. e-mail: [email protected]; fax: (410) 955-9677.
- ☆☆
Dr. Diehl is a consultant to the FDA panel reviewing TZDs manufactured by Takeda, is on the speakers bureau for Ascam Scandipharm, and is a consultant for metabasis insulin sensitizer.